CTEV (Claritev) Return-on-Tangible-Equity: 0.00% (As of Mar. 2026)


CTEV Claritev Corp CTEV
56 GF Score
Price $33.54
GF Value $31.33
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Claritev Return-on-Tangible-Equity?

Claritev CTEV -1.69% 56 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates CTEV with a GF Score™ of 56/100 and a GF Value™ of $31.33 (Fairly Valued). The stock has 6 warning signs investors should review. Among 582 Healthcare Providers & Services companies, Claritev ranks worse than 171821.13% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Claritev's annualized net income for the quarter that ended in Mar. 2026 was $-294.2 Mil. Claritev's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-4,455.0 Mil. Therefore, Claritev's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for Claritev's Return-on-Tangible-Equity or its related term are showing as below:

CTEV's Return-on-Tangible-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 9.965
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Claritev  (NYSE:CTEV) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Claritev Return-on-Tangible-Equity Related Terms


Claritev Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Claritev's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Claritev Return-on-Tangible-Equity Chart

Claritev Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Negative Tangible Equity 0.00 0.00 0.00 0.00

Claritev Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CTEV vs MDRX, EVH, PHR: Return-on-Tangible-Equity Comparison

For the Health Information Services subindustry, Claritev's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Claritev Return-on-Tangible-Equity vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Claritev's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Claritev's Return-on-Tangible-Equity falls into.


CTEV
56GF Score
Claritev Corp CTEV
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Claritev Return-on-Tangible-Equity Calculation

Claritev's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-284.282/( (-4545.441+-4464.357 )/ 2 )
=-284.282/-4504.899
=N/A %

Claritev's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-294.24/( (-4464.357+-4445.688)/ 2 )
=-294.24/-4455.0225
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Claritev (CTEV) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Claritev and its competitors. According to the industry distribution chart, Claritev ranks #999999 out of 582 companies in the Healthcare Providers & Services industry.
Is Claritev's Return-on-Tangible-Equity too high?
Claritev's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Claritev ranks #999999 out of 582 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Claritev has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Claritev's Return-on-Tangible-Equity compare to MDRX and EVH?
According to the Healthcare Providers & Services industry distribution chart, Claritev ranks #999999 out of 582 companies for Return-on-Tangible-Equity. This places Claritev in the lower half of its industry. The industry median Return-on-Tangible-Equity is 9.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 9.97, based on 582 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Claritev and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 9.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Claritev's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Claritev stock overvalued right now?
Based on GuruFocus' analysis, Claritev (CTEV) is currently considered Fairly Valued. The stock's GF Value™ is $31.33, compared to a current price of $33.54 — trading 7% above its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Claritev's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Claritev (CTEV), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Claritev (CTEV) Overvalued in 2026?

Based on GuruFocus' analysis, Claritev stock appears to be overvalued. The current stock price of $33.54 is trading 7% above its estimated GF Value™ of $31.33. GuruFocus considers Claritev to be Fairly Valued.

Key valuation signals for CTEV:

  • Return-on-Tangible-Equity: 0.00%
  • GF Value™: $31.33 vs. price of $33.54 (7% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the CTEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Claritev Business Description

Address 7900 Tysons One Place, Suite 400, McLean, VA, USA, 22102
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
56GF Score

Get the complete analysis for CTEV

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.54
Price
$31.33
GF Value